You are here

FDA Sets Action Date for Enzalutamide for Treatment of Prostate Cancer

On July 24, the companies had announced that the FDA had accepted the enzalutamide NDA filing for review and had granted Priority Review Designation.

Enzalutamide is an oral, once-daily, investigational androgen receptor signaling inhibitor. The drug inhibits androgen receptor signaling by inhibiting 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors.

In the phase III AFFIRM trial, side effects observed more frequently with enzalutamide compared with placebo included fatigue, diarrhea, and hot flush. Seizure was reported in less than 1% of enzalutamide-treated patients. Serious adverse events, adverse events causing patients to stop treatment, and adverse events causing death were lower in the enzalutamide group than in the placebo group.

For more information, visit the Medivation Web site.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs